^
Association details:
| Biomarker: | TP53 mutation + ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1196P - Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Published date:
09/13/2021
Excerpt:
Pts with ALK+ NSCLC previously treated with ≥1 2nd-gen ALK TKI (N=139) were treated with lorlatinib 100 mg QD in the ongoing Ph 1/2 study (NCT01970865)....TP53 mutations were found in 44 of 103 (42.7%) samples with detectable ctDNA at BL. ORR was 38.6% (95% CI: 24.4–54.5) and 45.8% (95% CI: 32.7–59.2) in pts with or without TP53 mutations, respectively; median DOR was 15.1 and 12.5 mo; and mPFS was 4.1 and 6.9 mo (hazard ratio [HR] = 0.83; 95% CI: 0.52–1.31)...in this heavily pretreated group of pts with ALK+ NSCLC, presence of TP53 mutations at BL was potentially associated with decreased lorlatinib efficacy...
Trial ID:
